Glycotest Overview

  • Founded
  • 2012

  • Status
  • Private

  • Employees
  • 2

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $10M

  • Investors
  • 2

Glycotest General Information


Operator of a liver diagnostics platform intended to commercialize blood tests for life-threatening liver cancers and fibrosis-cirrhosis. The company's platform provides non-invasive blood tests based on proprietary serum biomarkers, biomarker panels, and assay technology that exploit novel sugar-based disease signal chemistry, enabling patients with serious liver disease to avail of novel clinical laboratory testing services and experience early detection of liver cancer and chronic liver disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Primary Office
  • 613 Schiller Avenue
  • Suite 817
  • Merion, PA 19066
  • United States
+1 (484) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glycotest Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 05-Feb-2019 $10M 0000 0000 Completed Clinical Trials - Phase 3
3. Buyout/LBO 31-Dec-2016 00.000 00.00 00.000 Completed Clinical Trials - General
2. Accelerator/Incubator 05-Jun-2012 $500K $1.3M Completed Stealth
1. Later Stage VC 25-May-2012 $801K $801K Completed Stealth
To view Glycotest’s complete valuation and funding history, request access »

Glycotest Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Glycotest’s complete cap table history, request access »

Glycotest Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Operator of a liver diagnostics platform intended to commercialize blood tests for life-threatening liver cancers and fi
Diagnostic Equipment
Merion, PA
2 As of 2020
000 0000-00-00
00000000000 0000


at. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla par
0000000000 000000
Matsuyama, Japan
0000 As of 0000


aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur
000000000 (000)
Enid, OK
00 As of 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glycotest Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fuji Corporation Matsuyama, Japan 0000
0000 Corporation Enid, OK 00
You’re viewing 2 of 2 competitors. Get the full list »

Glycotest Executive Team (4)

Name Title Board Seat Contact Info
Charles Swindell Ph.D Chief Executive Officer, Board Member, Chief Operating Officer & Chief Scientific Officer
Jessica Rodriguez Clinical Operations Manager
Anand Mehta Ph.D Scientific and Medical Advisor
You’re viewing 3 of 4 executive team members. Get the full list »

Glycotest Board Members (13)

Name Representing Role Since
Ilian Iliev Ph.D Self Board Member 000 0000
Jing Yu Ph.D Fosun Pharma Board Member 000 0000
John Clarkson NetScientific Board Member 000 0000
Lily Zou Self Board Member 000 0000
Pei Jiang Glycotest Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Glycotest Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glycotest Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fosun Pharma Corporation Majority 000 0000 000000 0
NetScientific Venture Capital Minority 000 0000 000000 0
To view Glycotest’s complete investors history, request access »